China, Sept. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Safety and Efficacy of Obinutuzumab‑β for MOG Antibody‑Positive Optic Neuritis'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600132519
Registration Time: 2026/09/15
Type: Interventional study
Primary Sponsor: Eye Hospital, Wenzhou Medical University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342072
Published by HT Digital Content Services with permission from Health Daily Digest....